Trade Cyclerion Therapeutics, Inc. - CYCN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0244 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.6328 |
| Open | 2.6728 |
| 1-Year Change | -6.26% |
| Day's Range | 2.5728 - 2.8028 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 2.8028 | 0.1300 | 4.86% | 2.6728 | 2.8128 | 2.5728 |
| Feb 20, 2025 | 2.6328 | -0.1600 | -5.73% | 2.7928 | 2.8128 | 2.5928 |
| Feb 19, 2025 | 2.7928 | -0.2400 | -7.91% | 3.0328 | 3.0328 | 2.7728 |
| Feb 18, 2025 | 3.0328 | 0.0400 | 1.34% | 2.9928 | 3.1628 | 2.9428 |
| Feb 14, 2025 | 3.1028 | 0.2600 | 9.15% | 2.8428 | 3.1428 | 2.8428 |
| Feb 13, 2025 | 2.9928 | -0.2400 | -7.42% | 3.2328 | 3.2628 | 2.9628 |
| Feb 12, 2025 | 3.3428 | 0.2300 | 7.39% | 3.1128 | 3.4528 | 3.1128 |
| Feb 11, 2025 | 3.2328 | -0.4700 | -12.69% | 3.7028 | 3.7628 | 3.2228 |
| Feb 10, 2025 | 3.8528 | -0.2100 | -5.17% | 4.0628 | 4.2928 | 3.6028 |
| Feb 7, 2025 | 4.2428 | 0.0000 | 0.00% | 4.2428 | 4.7628 | 4.0728 |
| Feb 6, 2025 | 4.2428 | -0.1500 | -3.41% | 4.3928 | 4.4528 | 3.9928 |
| Feb 5, 2025 | 4.4628 | 0.2800 | 6.69% | 4.1828 | 5.0628 | 4.0428 |
| Feb 4, 2025 | 4.1828 | -1.2200 | -22.58% | 5.4028 | 5.4628 | 4.1528 |
| Feb 3, 2025 | 5.3628 | 1.4100 | 35.67% | 3.9528 | 6.1928 | 3.9128 |
| Jan 31, 2025 | 3.8628 | 0.5700 | 17.31% | 3.2928 | 4.4428 | 3.0228 |
| Jan 30, 2025 | 2.4628 | 0.1600 | 6.95% | 2.3028 | 2.6128 | 2.2928 |
| Jan 29, 2025 | 2.3528 | -0.0500 | -2.08% | 2.4028 | 2.4028 | 2.2928 |
| Jan 28, 2025 | 2.4128 | -0.1900 | -7.30% | 2.6028 | 2.6328 | 2.2728 |
| Jan 27, 2025 | 2.6028 | -0.0800 | -2.98% | 2.6828 | 2.7528 | 2.5728 |
| Jan 24, 2025 | 2.6228 | -0.2200 | -7.74% | 2.8428 | 2.8828 | 2.5628 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cyclerion Therapeutics, Inc. Company profile
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com